Apollo Hospitals reported Q2 FY27 net profit of ₹3,311 Cr on revenue of ₹32,677 Cr, with profit up +12.3% year-on-year and ahead of street estimates. The stock was little changed as investors weighed the margin trend and management's outlook for the rest of the year.
Last 8 quarters / 3 years
| Period | Revenue | Net Profit | EPS | YoY | QoQ |
|---|---|---|---|---|---|
| Q3 FY25 | ₹22,432 Cr | ₹2,857 Cr | ₹199.15 | — | — |
| Q4 FY25 | ₹23,927 Cr | ₹2,674 Cr | ₹186.35 | — | -6.4% |
| Q1 FY26 | ₹23,594 Cr | ₹2,898 Cr | ₹201.96 | — | +8.4% |
| Q2 FY26 | ₹24,940 Cr | ₹2,949 Cr | ₹205.52 | — | +1.8% |
| Q3 FY26 | ₹25,552 Cr | ₹3,016 Cr | ₹210.18 | +5.5% | +2.3% |
| Q4 FY26 | ₹27,783 Cr | ₹2,709 Cr | ₹188.78 | +1.3% | -10.2% |
| Q1 FY27 | ₹30,254 Cr | ₹3,889 Cr | ₹271.04 | +34.2% | +43.6% |
| Q2 FY27 | ₹32,677 Cr | ₹3,311 Cr | ₹230.78 | +12.3% | -14.9% |
Last 4 quarters
Recent large transactions
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 9 Sep 2026 | Societe Generale | SELL | 25,37,684 | ₹6,649.86 |
Several brokerages maintained a positive stance on Apollo Hospitals, citing improving return ratios and a clearer growth runway, while a few flagged valuations as the key risk.
Several brokerages maintained a positive stance on Apollo Hospitals, citing improving return ratios and a clearer growth runway, while a few flagged valuations as the key risk.
Apollo Hospitals announced an interim dividend, with the record date set for later this month. The payout is consistent with the company's stated capital-return policy.
Apollo Hospitals entered a strategic partnership to widen its addressable market. Management expects the tie-up to contribute modestly to revenue over the next few quarters.
Apollo Hospitals reported revenue and profit broadly in line with Street expectations, with management flagging stable demand and a healthy order pipeline into the second half.
In an exchange filing, Apollo Hospitals said its board cleared a multi-year investment to expand capacity, aimed at meeting demand and improving operating leverage over the medium term.
Tap a metric label to learn what it means.
Hospitals
| Company | P/E | 1Y |
|---|---|---|
| Sun Pharmaceutical ₹4,27,000 Cr | 48.5 | +36.2% |
| Cipla ₹1,23,000 Cr | 47.7 | +6.9% |
| Dr. Reddy's Laboratories ₹1,07,000 Cr | 50.3 | +6.6% |
| Divi's Laboratories ₹1,57,000 Cr | 39.8 | +7.0% |
Apollo Hospitals is a leading Indian company in the hospitals space within the Healthcare sector. It is a constituent of the Nifty 50 and is actively tracked by institutional and retail investors.